Tirzepatide, a novel dual glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) receptor agonist, has gained recognition as an effective option for managing both T2DM and obesity by targeting multiple metabolic pathways (5–8). This evidence concerns the gene GLP1R and obesity disorder.